| 
| 
| 
Alimta is a treatment for Malignant Pleural Mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. Alimta is given with cisplatin, another anti-cancer medicine (chemotherapy) when surgery is not an option.
Alimta is a type of chemotherapy. Alimta was approved by the FDA as a single agent (used alone) for [...]
Sometimes, mesothelioma patients seek out supplements or replacements for their traditional treatment plan. Alternative treatments provide means of relieving stress, coping with mental exhaustion, easing the side effects of traditional treatments, and helping the patient take an active role in their fight against disease.
Acupuncture is one of the most recognizable alternative treatment plans. [...]
In the race for a novel anti-cancer therapy drug between two firms, one company is clearly ahead. Alfacell Corp., an east-coast biotech company, is in its second Phase III trial for a drug that uses an enzyme to interact with RNA to treat cancer. Quintessence Bioscience, of the midwest, is developing a very [...]
Alfacell Corporation (NASDAQ:ACEL) today announced that it has confirmed that 316 evaluable events (patient deaths) have occurred in the confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), for the treatment of patients with unresectable malignant mesothelioma (UMM). In accordance with the statistical plan for the trial, the company has begun the process [...]
A drug that can help protect those who have been exposed to asbestos has resulted from a study, published in Science Magazine, which - for the first time - explains how asbestos fibers lead to the chronic lung inflammation that causes asbestosis and mesothelioma cancer.
The study was conducted by Prof. Jürg Tschopp of the University [...]
In the February 2008 issue of the American Journal of Clinical Oncology, researchers from Columbia University reported that combined resection, intraperitoneal chemotherapy, and whole abdominal radiation therapy has shown to be an effective treatment for malignant peritoneal mesothelioma.
Peritoneal mesothelioma accounts for less than 20 percent of all mesothelioma cases and its latency period is even [...]
It’s universally accepted that asbestos exposure increases the risk of malignant mesothelioma, but it can be a factor in the development of infectious disease as well because of its negative impact on the immune system. Tuberculosis—or TB—kills more people world-wide than any other infectious disease. While the victims of TB used to be [...]
Obtaining cancer research funding can be trying. Often, seeking money for research is a matter of pleasing supervisors of National Institutes of Health or appeasing gatekeepers of advocacy groups.
A new prize, however, is offering $1 million annually to encourage innovative cancer treatment research. The Gotham Prize was established in May by two hedge fund managers [...]
In the February 2008 issue of the American Journal of Clinical Oncology, researchers from Columbia University reported that combined resection, intraperitoneal chemotherapy, and whole abdominal radiation therapy has shown to be an effective treatment for malignant peritoneal mesothelioma.
Peritoneal mesothelioma accounts for less than 20 percent of all mesothelioma cases and its latency period is even [...]